Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
It is only the second generic application approved by the USFDA
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
It signals Cordis' renewed investment in innovation
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
The product will be manufactured at Lupin’s facility in Goa, India
Subscribe To Our Newsletter & Stay Updated
